Baird Capital Invests in Newmarket Strategy
LONDON (08 January 2025) - Today, Newmarket Strategy (“Newmarket”), an independent life sciences consultancy and market access specialist, announced a growth capital investment from Baird Capital’s Global Private Equity Fund. The investment will support the company’s continued growth as an independent leader in pharmaceutical services and healthcare advisory.
Founded in 2021, Newmarket applies deep market access, commercial and policy expertise to the health and life sciences sector. The team works with clients to assess market opportunities, secure reimbursement from national and local payors, and drive the uptake of health innovations. Clients include global pharmaceuticals and biotech, med-tech, diagnostics, digital health, private equity and healthcare services providers.
We are thrilled to partner with Baird Capital for Newmarket’s next stage of growth. We were hugely impressed by Baird Capital’s team and partnership style, by their proven expertise and by the commitment they show to our sector. We are immensely proud of the hard work by all our team to date, and of the continued faith shown by our valued clients.
Ed Jones, Chief Executive at Newmarket Strategy
“We are excited to support Newmarket’s ambition to be the leader in its field . The team brings a high level of expertise, and the services they provide address a critical need across the clients they serve. This investment in Newmarket follows a number of previous investments that we have made in the Pharma Services segment including Campbell Alliance, Prescient and Blue Matter. We look forward to working with Ed and the team to grow Newmarket over the upcoming years.
Michael Holgate, Partner with Baird Capital’s Global Private Equity Team
Baird Capital was advised by Squire Patton Boggs (Legal), Clearwater (Corporate Finance), T4 (Voice of Customer), Candesic (Commercial Diligence), BDO (Financial & Tax), New Street Consulting (Management), and WTW (Insurance); Newmarket was advised by JMW (Legal) and MHA (Corporate Advisory).
About Newmarket
Newmarket Strategy is an independent life sciences advisor and market access specialist, founded in London in 2021 by Berkeley Greenwood, Ed Jones and James (Lord) O’Shaughnessy. Its mission is to drive access to health innovations which have the power to improve, transform and save lives. Newmarket applies deep expertise on the policies, processes and technical requirements which govern the reimbursement of health and life sciences products.
About Baird Capital
Baird Capital manages two investment platforms: Global Private Equity and U.S. Venture Capital and makes investments in B2B technology & services-focused companies around the world. Baird Capital partners with entrepreneurs and, leveraging its executive networks, strives to build exceptional companies. Baird Capital provides operational support to its portfolio companies through teams on the ground in the United States, Europe and Asia, a proactive portfolio operations team and a deep network of relationships, which together strive to deliver enhanced shareholder value. Baird Capital is the direct private investment arm of Robert W. Baird & Co. Committed to being a great place to work, Baird ranked No. 34 on the 2024 Fortune 100 Best Companies to Work For® list – its 21st consecutive year on the list. For more information, please visit BairdCapital.com.
Baird Capital Partners Europe Limited is authorised and regulated by the Financial Conduct Authority.
For More Information
Baird Public Relations
publicrelations@rwbaird.com
414-765-7250
H/Advisors Maitland
baird-maitland@h-advisors.global
+44 (0) 207 379 5151
